The Yusuf Hamied-led Cipla has been busy tying up with a US company. The non-executive chairman of $2.3 billion (revenue) generics maker Cipla’s US subsidiary Cipla Therapeutics and SIGA Technologies, Inc (SIGA), a commercial-stage pharmaceutical company focussed on the health security market, have entered into a strategic partnership to deliver sustained innovation and access to novel anti-bacterial drugs, particularly against bio-threats. On the development front, recently, the company had tied up with MSD (a trade name of Merck & Co Inc, Kenilworth, NJ, USA) to make, distribute investigational drug molnupiravir in India. MSD is developing molnupiravir in collaboration with Ridgeback Biotherapeutics and this agreement is a part of Cipla’s efforts to enhance global access to the treatment for patients affected by the pandemic. Meanwhile, Cipla, a global pharmaceutical company focussed on complex generics, is deepening its portfolio in the markets of India, South Africa, North America and key regulated and emerging markets. Globally, North America business grew by 6% year on year, led by continued expansion in market share of Albuterol and other assets along with growth in the institutional channel.